Fabrikstrasse 2, 4056 Basel
Location: Basel
Discipline: Medicine/Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Medicine - Jul 19
Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to contribute significantly to atopic dermatitis (AD), a form of eczema and a severe dermatologic condition with high prevalence and significant unmet medical ne
Medicine - Jul 18

Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisq

Medicine - Jun 29

Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe First CHMP opinion for a CAR-T cell therapy i

Medicine - Jun 28

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine Results from a one-year study of efficacy a

Business - Jul 18

Net sales grew 5% (cc , +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 millio

Business - Jun 29

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn Alcon strategic review concludes that 100% s

Medicine - Jun 27

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Study

website preview


Medicine and Life Sciences